Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

ries123 35 posts  |  Last Activity: Sep 25, 2015 12:43 AM Member since: Jun 26, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Check out Insmed website

    by insmhistorian Sep 25, 2015 12:07 AM
    ries123 ries123 Sep 25, 2015 12:43 AM Flag

    Nice! Powered by purpose, like it...

    Sentiment: Strong Buy

  • BRIDGEWATER, N.J., Sept. 23, 2015 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the needs of patients with rare diseases, today reported that company management will participate at the 2015 Leerink Partners Rare Disease Roundtable taking place at Le Parker Meridien Hotel in NY on September 30. Andy Drechsler, chief financial officer of Insmed, will participate in an analyst-led fireside chat at 11:30 AM ET.

    Sentiment: Strong Buy

  • Reply to

    Presentations in Amsterdam next week

    by justarook04 Sep 22, 2015 8:05 AM
    ries123 ries123 Sep 22, 2015 8:09 AM Flag

    Beat me to it.. thanks

    Sentiment: Strong Buy

  • BRIDGEWATER, N.J. , Sept. 22, 2015 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the needs of patients with rare diseases today reported two ARIKAYCE™ (liposomal amikacin for inhalation) posters will be presented at the European Respiratory Society (ERS) International Congress taking place in Amsterdam from September 26-30.

    Sentiment: Strong Buy

  • BRIDGEWATER, N.J., Sept. 14, 2015 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the needs of patients with rare diseases today reported new nontuberculous mycobacteria (NTM) lung disease information and a pharmacokinetic analysis of ARIKAYCE™ (liposomal amikacin for inhalation) will be presented at the 2015 joint meeting of the Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and the International Congress of Chemotherapy and Infection (ICC). ICAAC/ICC 2015 is taking place in San Diego, California from September 17-21.

    Sentiment: Strong Buy

  • Reply to

    Why this MB never gets new posters

    by terry_insm Aug 31, 2015 8:26 AM
    ries123 ries123 Aug 31, 2015 8:48 AM Flag

    The only new posters are the ones you create... It must be lonely with just you.. and you.. and you...

    Sentiment: Strong Buy

  • ries123 by ries123 Aug 6, 2015 9:45 AM Flag

    Did I saw that right ? 28,66 on the ticker...?

    -wow-

    Sentiment: Strong Buy

  • Reply to

    Second Quarter and Update

    by ries123 Aug 6, 2015 7:37 AM
    ries123 ries123 Aug 6, 2015 8:37 AM Flag

    There are always reasons for the crooks to push it down.. but momentum was and is strong.

    Sentiment: Strong Buy

  • Reply to

    Second Quarter and Update

    by ries123 Aug 6, 2015 7:37 AM
    ries123 ries123 Aug 6, 2015 7:42 AM Flag

    •INS1009 advancing toward clinical development. The company is completing a number of IND-enabling preclinical studies and expects to submit its Investigational New Drug (IND) Application and initiate a phase 1 clinical study of INS1009 in the fourth quarter of 2015. INS1009 is the company's nebulized treprostinil prodrug that is being developed for pulmonary arterial hypertension (PAH).
    •Pre-commercial and manufacturing activities advancing. NTM disease awareness campaigns are advancing in Europe and the U.S. In addition, the build-out of additional third-party commercial-scale manufacturing capacity is proceeding according to plan and the company is on track to have two sources of ARIKAYCE supply established by year-end.
    •Significantly strengthened balance sheet. Insmed completed a successful equity offering in April raising net proceeds of $222.9 million and finished the second quarter with $335 million in cash. The company's cash operating expenses for the six months ended June 30, 2015 were approximately $46 million.
    •Management team enhancements. The company continues to make key additions to its leadership team, including the recent additions of Ela Bochenek, vice president global compliance and George Georges, MD, vice president global medical affairs. Ms. Bochenek's prior experience includes NPS Pharmaceuticals, C.R. Bard, Schering-Plough, and Bristol-Myers Squibb. Dr. Georges previously served in numerous U.S. and global medical affairs leadership roles at InterMune, GlaxoSmithKline, and Sanofi.

    Sentiment: Strong Buy

  • Second Quarter and Recent Highlights
    •Global phase 3 study expanding. Patient enrollment is advancing in the company's global phase 3 study of ARIKAYCE™ (liposomal amikacin for inhalation or LAI) in nontuberculous mycobacteria (NTM) lung disease (the "212" or CONVERT™ study). The company has secured health authority clearance in 10 countries with CONVERT study sites. In addition to the U.S., patient recruitment is underway in Australia, Canada, Europe, and New Zealand. With strong interest among clinical investigators, Insmed is expanding the total number of CONVERT clinical sites to more than 100.
    •Preliminary long-term data from phase 2 clinical study (112 study) support durability of ARIKAYCE treatment effect. One-year post-ARIKAYCE treatment follow-up data is now available for 14 of 23 patients who achieved culture conversion during the 196-day 112 study. Twelve of the 14 patients remained culture negative for NTM at their one-year follow-up visit. Cultures from the remaining two patients grew in liquid medium only and not on solid medium, which may represent contamination (false-positive) or a new infection rather than a relapse of the original infecting strain.
    •EMA regulatory review progressing. The European Medicine Agency's (EMA) review of the company's marketing authorization application (MAA) for ARIKAYCE is ongoing. Insmed has received the EMA's 120-day questions and anticipates responding before the end of 2015.
    •ATU approval secured in France and first product shipped. The French National Agency for Medicines and Health Products Safety (ANSM) granted LAI a nominative Temporary Authorization for Use (Autorisation Temporaire d'Utilisation or ATU). Pursuant to this program, in July the company shipped product after receiving a request from a physician for a patient in France. Expanded access programs are generally intended to make products available to patients before they are approved or commercially available in accordance with local regulations.
    •INS10

    Sentiment: Strong Buy

  • ries123 by ries123 Aug 6, 2015 4:35 AM Flag

    Will Lewis, president and chief executive officer, and Andy Drechsler, chief financial officer, will host a conference call for investors beginning at 8:30 a.m. ET on Thursday, August 6, 2015 to discuss the second quarter 2015 financial results AND TO PROVIDE A BUSINESS UPDATE.

    I sure hope he did his homework...

    Sentiment: Strong Buy

  • ries123 ries123 Jul 29, 2015 5:07 AM Flag

    2013... get a life !

    Sentiment: Strong Buy

  • Reply to

    Back above $26

    by jd39souza98 Jul 28, 2015 10:57 AM
    ries123 ries123 Jul 28, 2015 1:55 PM Flag

    Almost back above $27... !

    Sentiment: Strong Buy

  • Reply to

    Heees backk ! This is the INSM bd?

    by terry_insm Jul 21, 2015 8:01 AM
    ries123 ries123 Jul 21, 2015 8:09 AM Flag

    Liar-Liar-Land...

    Sentiment: Strong Buy

  • Reply to

    The silence is telling

    by dorianrivers21 Jul 14, 2015 8:36 AM
    ries123 ries123 Jul 14, 2015 9:58 AM Flag

    JD, blasedp3l is one of the freak clones who invaded the board... no need to reply to them...

    Sentiment: Strong Buy

  • Reply to

    Today

    by justarook04 Jun 22, 2015 8:41 AM
    ries123 ries123 Jun 22, 2015 9:55 AM Flag

    25,10 it is right now ...

    Sentiment: Strong Buy

  • Insmed to Participate at the JMP Securities Life Sciences Conference

    BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the needs of patients with rare diseases, today announced that company management will participate at the 2015 JMP Securities Life Sciences Conference 2015 taking place at The St. Regis New York from June 23 to June 24. Andy Drechsler, chief financial officer of Insmed, will present a corporate overview on Wednesday, June 24 at 11:30 AM ET.

    Sentiment: Strong Buy

  • Reply to

    Citigroup

    by justarook04 Jun 9, 2015 7:54 AM
    ries123 ries123 Jun 9, 2015 8:33 AM Flag

    Not too bad ;-) and still 15% from where we are right now..

    Sentiment: Strong Buy

  • SEC Filing as per 5/12/15

    Sentiment: Strong Buy

  • BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on developing orphan treatments for rare pulmonary diseases, today reported that three ARIKAYCE™ abstracts and three INS1009 abstracts will be presented at the American Thoracic Society (ATS) 2015 International Conference taking place in Denver from May 15 - 20. ARIKAYCE, or liposomal amikacin for inhalation, is in late-stage development for the treatment of adult patients with nontuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium complex (MAC). INS1009, an inhaled prodrug formulation of treprostinil, is the company's clinical candidate for pulmonary arterial hypertension.

    Sentiment: Strong Buy

INSM
12.78-0.60(-4.48%)Feb 5 4:00 PMEST